Biography: Theodoros Teknos, MD
- President and Scientific Director, UH Seidman Cancer Center
- Professor, CWRU School of Medicine
Certifications & Memberships
- Otolaryngology - Head and Neck Surgery - American Board of Otolaryngology - Head and Neck Surgery
Fellowship | Head and Neck Oncology
Head and Neck Oncology - Vanderbilt University Medical Center (1996 - 1997)
Residency | Otolaryngology
Otolaryngology - Massachusetts Eye And Ear Infirmary (1992 - 1996)
Internship | General Surgery
General Surgery - Henry Ford Hospital (1991 - 1992)
Harvard Medical School (1991)
Wayne State University (1987)
Theodoros (Ted) Teknos, MD is President & Scientific Director for the University Hospitals Seidman Cancer Center at University Hospitals Cleveland Medical Center and Deputy Director of the Case Comprehensive Cancer Center. Dr. Teknos also has been appointed the Jane and Lee Seidman Chair in Cancer Innovation and he holds the title of Professor at Case Western Reserve University School of Medicine. He is board certified in Otolaryngology-Head and Neck Surgery. In November 2020 he was bestowed with the Distinguished Physician designation in recognition of exceptional service that personifies UH’s mission: To Heal. To Teach. To Discover.
In his role as President & Scientific Director, Dr. Teknos leads the development of strategic, business and marketing plans for UH Seidman, including cancer-related palliative care, integrative care and interface with UH Hospice care. He oversees all inpatient and ambulatory cancer care delivered at facilities across the UH system. Dr. Teknos provides leadership of UH Seidman’s academic components and the Clinical Trials Unit and directs UH Seidman’s involvement in the Case Comprehensive Cancer Center.
Dr. Teknos is a renowned clinician and academic authority in head and neck cancers, and he will continue his surgical practice, clinical trials and research here at UH. Dr. Teknos has been published in over 200 peer-reviewed journals and publications, and he is a frequent presenter at major scientific meetings. He is active in numerous professional societies, including the American Society of Clinical Oncology, the International Academy of Oral Oncology, the American Association for Cancer Research, and the American College of Surgeons.
Dr. Teknos came to University Hospitals in October 2017 from The Ohio State University Wexner Medical Center, where he has served in several leadership roles since 2008. He served as Professor and Chair, Department of Otolaryngology – Head and Neck Surgery. Prior to his position at Ohio State, he was Division Chief, Head & Neck Oncology Division, Department of Otolaryngology, at the University of Michigan Health System in Ann Arbor. From 2007 to 2014, Dr. Teknos co-chaired a Task Force on Recurrent & Metastatic Disease for the National Cancer Institute’s Head & Neck Cancer Steering Committee.
Dr. Teknos earned his medical degree from Harvard Medical School. He completed his otolaryngology residency at Massachusetts Eye & Ear Infirmary/Harvard Combined Program, Boston, and a fellowship in head and neck oncology, skull base and microvascular reconstruction at Vanderbilt University Medical Center in Nashville.
Related Blog Articles
The UH Connor Whole Health Integrative Oncology Clinic provides physician-guided massage therapy and acupuncture to ease cancer patients’ pain.
Immunotherapy is a new, groundbreaking approach to treating cancer that harnesses the body’s own natural defenses to fight tumors.
Whether you should get vaccinated depend on many factors, such as the type of vaccine, the type of cancer you have or have had, if you are in active treatment or if your immune system is working properly.
A recent study from UH Seidman Cancer Center suggests biological differences in tumors could be driving differences in outcomes.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Theodoros Teknos did not disclose any Outside Relationships with Industry.